title: Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography.
abstract: OBJECTIVE
  In meningioma patients with postoperative residual masses, recurrent or primarily inoperable tumors, positron emission tomography (PET) with [(11)C]-L-methionine was used to evaluate treatment efficacy of IFN-alpha.
  
  
  METHODS
  Twelve patients were treated with IFN-alpha at a dose of 1.5-5 million IU s.c. daily. PET, computed tomography, and/or magnetic resonance imaging were performed in all patients before and, at regular intervals, during IFN-alpha treatment. The ratio of tumor hot-spot uptake to cerebellar uptake or to cortex uptake was calculated. This ratio estimates the relative methionine accumulation in the tumor and presumably the proliferative activity in the tumor.
  
  
  RESULTS
  During IFN-alpha treatment, PET demonstrated a mean relative percentage of reduction in the uptake ratio (MRelR) of 22.3% in the meningiomas. In nine patients who were considered responders, defined as patients with a positive MRelR, the MRelR was 30.4%. For the three nonresponders, defined as patients with a negative MRelR, the MRelR was -1.8%. Three patients were followed for a long time: two patients for 8 years and one patient for 4 years and 6 months; the two patients followed for 8 years are still on IFN. The volumes of these tumors were constant or showed a slight decrease. No correlation was found between histopathological diagnosis (PAD) WHO grading I-III of meningiomas and response to IFN-alpha treatment.
  
  
  CONCLUSIONS
  PET was judged a useful method to predict which patients are suitable for long-term treatment with IFN-alpha and also for dose finding. In five patients treated from 9 months to 8 years, IFN-alpha seemed to be an effective oncostatic drug. The clinical usefulness of IFN-alpha, taking adverse reactions into account, must be evaluated in a larger series of patients.
authors.affiliation: Department of Neurology, University Hospital, SE-75185 Uppsala, Sweden. Carin.Muhr@neurologi.uu.se
authors.forename: C
authors.initials: C
authors.lastname: Muhr
authors.forename: O
authors.initials: O
authors.lastname: Gudjonsson
authors.forename: A
authors.initials: A
authors.lastname: Lilja
authors.forename: M
authors.initials: M
authors.lastname: Hartman
authors.forename: Z J
authors.initials: ZJ
authors.lastname: Zhang
authors.forename: B
authors.initials: B
authors.lastname: Långström
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002250:Carbon Radioisotopes; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008577:Meningeal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008579:Meningioma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008715:Methionine; D008875:Middle Aged; D013997:Time Factors; D014055:Tomography, Emission-Computed; D016896:Treatment Outcome
chemical_list: D002250:Carbon Radioisotopes; D016898:Interferon-alpha; D008715:Methionine